AIM: This study aimed to evaluate the efficacy and safety of
sofosbuvir (SOF)/ribavirin (RBV) and SOF/daclatasvir (DAC)/
RBV in Egyptian patients with hepatitis C virus (HCV)-related
cirrhosis and to demonstrate the effects of these treatments on their
haematological and biochemical profiles.
PATIENTS AND METHODS: A prospective study was performed
on 200 patients with HCV-related cirrhosis. Group 1 received SOF
and RBV for 24 weeks, and Group 2 received SOF, DAC and RBV
for 12 weeks.
RESULTS: A sustained virological response (SVR) was achieved
in 75 (75%) and 96 (96%) patients in Groups 1 and 2, respectively.
The mean haemoglobin (Hb) level and platelet count decreased
significantly at the end of treatment in both groups, and the percent
decrease was significantly higher in Group 1 than in Group 2. The
mean albumin, alanine aminotransferase (ALT), and aspartate
aminotransferase (AST) levels decreased significantly at the end
of treatment in both groups. There was a significant increase in the
mean total bilirubin level in both groups at the end of treatment. The
percent increase in the mean indirect bilirubin level was significantly
higher in Group 2 than in Group 1. There was improvement in the
Fibrosis-4 (FIB-4) score at the end of treatment in both groups. This
improvement was maintained to SVR 12 in both groups.
CONCLUSION: Patients with cirrhosis who received SOF, DAC and
RBV for 12 weeks had a significantly higher SVR12 rate than those
who received SOF and RBV for 24 weeks. In patients who achieved
SVR, there was improvement in liver function parameters and the
FIB4 score at the time of SVR12 in compared to baseline values.